Kroger Specialty Infusion CA, LLC v. Marni Tazamisha Sturns and Bioplus Specialty Pharmacy Services LLC

CourtCourt of Appeals of Texas
DecidedMay 16, 2024
Docket05-22-01276-CV
StatusPublished

This text of Kroger Specialty Infusion CA, LLC v. Marni Tazamisha Sturns and Bioplus Specialty Pharmacy Services LLC (Kroger Specialty Infusion CA, LLC v. Marni Tazamisha Sturns and Bioplus Specialty Pharmacy Services LLC) is published on Counsel Stack Legal Research, covering Court of Appeals of Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kroger Specialty Infusion CA, LLC v. Marni Tazamisha Sturns and Bioplus Specialty Pharmacy Services LLC, (Tex. Ct. App. 2024).

Opinion

AFFIRMED and Opinion Filed May 16, 2024

S In The Court of Appeals Fifth District of Texas at Dallas No. 05-22-01276-CV

KROGER SPECIALTY INFUSION CA, LLC, Appellant V. MARNI TAZAMISHA STURNS AND BIOPLUS SPECIALTY PHARMACY SERVICES LLC, Appellee

On Appeal from the 193rd Judicial District Court Dallas County, Texas Trial Court Cause No. DC-21-10498

MEMORANDUM OPINION Before Justices Pedersen, III, Goldstein, and Garcia Opinion by Justice Garcia This appeal arises from the trial court’s entry of a no evidence summary

judgment in favor of Bioplus Specialty Pharmacy Services, LLC (“Bioplus”) and

Marni Tazamisha Sturns (“Sturns”) on Kroger Specialty Infusion CA, LLC’s

(“Kroger’s”) claims for misappropriation of trade secrets, tortious interference, and

breach of contract. As expressed in several issues, Kroger argues the trial court erred

in granting summary judgment on all of its claims. As discussed below, we affirm

the trial court’s judgment. I. BACKGROUND

Kroger is a clinical pharmacy dedicated to serving patients with chronic

illnesses requiring complex care. Kroger serves its patients by offering

comprehensive therapy management programs as well as injectable and oral

pharmaceutical treatments for a wide variety of chronic illnesses and conditions.

Sturns began working for Kroger as a special accounts manager in the

immunoglobin department in April 2015 and signed a noncompete agreement (the

“Agreement”) in connection with her employment. The Agreement had a one-year

term and covered a defined geographic area (the “Restricted Area”) that included

Sturns’s sales territory and any state adjacent to that territory. The Agreement

restricts Sturns from, among other things: (a) working for a competitor for one year

after termination in the Restricted Area (as defined in the Agreement); (b) soliciting

customers, referral sources, and patients in the Restricted Area (as defined in the

Agreement); and (c) using Kroger’s confidential information to compete unfairly.

In March 2021, Sturns left Kroger of her own accord and began working as a

sales representative for Bioplus. Kroger believed that Sturns was violating the

Agreement and initiated the underlying lawsuit against Sturns and Bioplus.

Kroger’s Original Petition and Application for Injunctive relief asserted

claims for breach of contract, tortious interference, and misappropriation of trade

secrets under the Texas Uniform Trade Secrets Act (“TUTSA”). See TEX. CIV. PRAC.

& REM. CODE ANN. §§134.001 et. seq. The petition requested injunctive relief,

–2– compensatory damages for harm “not susceptible to injunctive relief,” punitive

damages, and costs and attorney’s fees.

Discovery was conducted under a level three discovery control plan. The

court’s September 13, 2021 scheduling order set a May 3, 2022 discovery deadline.

Four months after the entry of the order, Kroger served written discovery on Bioplus

and Sturns. Bioplus and Sturns both responded on April 4, 2022.

On May 3, 2022, the day that discovery closed, Kroger moved to modify the

scheduling order and extend the time for discovery. The trial court denied the

requested extension and modification, but continued the trial date.1

Kroger filed a motion to compel on May 12, 2022. The motion is not included

in the record, and the record does not reflect that the motion was heard or otherwise

submitted for the court’s consideration.2

Sturns and Bioplus filed no evidence motions for summary judgment, and

Kroger responded to both motions. Kroger’s response relied on its verified petition,

its own answers to interrogatories, and the declaration of Ryan McGrath (the

“Declaration”) to defeat summary judgment.

The court conducted a hearing and granted summary judgment in favor of

Bioplus and Sturns on all of Kroger’s claims. This timely appeal followed.

1 Kroger does not challenge the denial of the motion on appeal. 2 The docket sheet includes an entry for a “Notice of Hearing/Fiat” on May 31, 2022 but there is no indication the court conducted a hearing. –3– II. ANALYSIS

A. Standard of Review and Applicable Law

After adequate time for discovery, a party may move for summary judgment

asserting that there is no evidence of one or more essential elements of a claim on

which the nonmovant would have the burden of proof at trial. See TEX. R. CIV. P.

166a(i). The rule requires that a no-evidence motion specifically state the element or

elements for which there is no evidence. TEX. R. CIV. P 166a(i); Cmty. Health Sys.

Prof’l Servs. Corp. v. Hansen, 525 S.W.3d 671, 695 (Tex. 2017).

Once the movant specifies the elements lacking evidence, the burden shifts to

the respondent to raise a fact issue on the challenged elements. See TEX. R. CIV. P

166a(i); Sw. Elec. Power Co. v. Grant, 73 S.W.3d 211, 215 (Tex. 2002); see also

Bradford Ptrs. II, L.P. v. Fahning, 231 S.W.3d 513, 516–17 (Tex. App.—Dallas

2007, no pet.). We review a no-evidence motion for summary judgment under the

same legal sufficiency standard used to review a directed verdict. King Ranch, Inc.

v. Chapman, 118 S.W.3d 742, 750–51 (Tex. 2003). A no-evidence challenge will be

sustained when: (1) there is a complete absence of evidence of a vital fact; (2) the

trial court is barred by rules of law or of evidence from giving weight to the only

evidence offered to prove a vital fact; (3) the evidence offered to prove a vital fact

is no more than a mere scintilla; or (4) the evidence conclusively establishes the

opposite of the vital fact. Merriman v. XTO Energy, Inc., 407 S.W.3d 244, 248 (Tex.

2013).

–4– More than a scintilla of evidence exists when the evidence would permit

reasonable and fair-minded people to differ in their conclusions. King Ranch, 118

S.W.3d at 751. Evidence that is so weak as to do no more than create a mere surmise

or suspicion does not create a fact issue. Kia Motors Corp. v. Ruiz, 432 S.W.3d 865,

875 (Tex. 2014). In our review, we take as true all evidence favorable to the

nonmovant, indulging every reasonable inference and resolving any doubts in his

favor. King Ranch, 118 S.W.3d at 751. We review a trial court’s summary judgment

de novo. Valence Operating Co. v. Dorsett, 164 S.W.3d 656, 661 (Tex. 2005).

B. Adequate Time for Discovery

The parties had eight months to complete discovery after the trial court

entered the scheduling order. Kroger argues that the trial court’s ruling was

erroneous because there was inadequate time for discovery. We disagree.

A no-evidence motion for summary judgment may be granted only after “an

adequate time for discovery.” See TEX. R. CIV. P. 166a(i). But the rule does not

require that discovery be completed, only that there was “adequate time.” Id. see

also, Dishner v. Huitt–Zollars, Inc., 162 S.W.3d 370, 376 (Tex. App.—Dallas 2005,

no pet). The adequacy of the time for discovery is determined by the nature of the

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Valence Operating Co. v. Dorsett
164 S.W.3d 656 (Texas Supreme Court, 2005)
Arkoma Basin Exploration Co. v. FMF Associates 1990-A, Ltd.
249 S.W.3d 380 (Texas Supreme Court, 2008)
Hou-Tex, Inc. v. Landmark Graphics
26 S.W.3d 103 (Court of Appeals of Texas, 2000)
Bradford Partners II, L.P. v. Fahning
231 S.W.3d 513 (Court of Appeals of Texas, 2007)
Frank's International, Inc. v. Smith International, Inc.
249 S.W.3d 557 (Court of Appeals of Texas, 2008)
Brownlee v. Brownlee
665 S.W.2d 111 (Texas Supreme Court, 1984)
CA PARTNERS v. Spears
274 S.W.3d 51 (Court of Appeals of Texas, 2008)
Thompson v. Curtis
127 S.W.3d 446 (Court of Appeals of Texas, 2004)
James L. Gang & Associates, Inc. v. Abbott Laboratories, Inc.
198 S.W.3d 434 (Court of Appeals of Texas, 2006)
Ling v. BDA&K Business Services, Inc.
261 S.W.3d 341 (Court of Appeals of Texas, 2008)
Tenneco Inc. v. Enterprise Products Co.
925 S.W.2d 640 (Texas Supreme Court, 1996)
Southwestern Electric Power Co. v. Grant
73 S.W.3d 211 (Texas Supreme Court, 2002)
Stewart v. Sanmina Texas L.P.
156 S.W.3d 198 (Court of Appeals of Texas, 2005)
Dishner v. Huitt-Zollars, Inc.
162 S.W.3d 370 (Court of Appeals of Texas, 2005)
Stone v. Midland Multifamily Equity REIT
334 S.W.3d 371 (Court of Appeals of Texas, 2011)
King Ranch, Inc. v. Chapman
118 S.W.3d 742 (Texas Supreme Court, 2003)
Restaurant Teams International, Inc. v. MG Securities Corp.
95 S.W.3d 336 (Court of Appeals of Texas, 2002)
Twister B v. v. Newton Research Partners, LP
364 S.W.3d 428 (Court of Appeals of Texas, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
Kroger Specialty Infusion CA, LLC v. Marni Tazamisha Sturns and Bioplus Specialty Pharmacy Services LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/kroger-specialty-infusion-ca-llc-v-marni-tazamisha-sturns-and-bioplus-texapp-2024.